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Abstract
Background: The optimal management for severe sprains (Grades II and III) of the lateral ligament
complex of the ankle is unclear. The aims of this randomised controlled trial are to estimate (1)
the clinical effectiveness of three methods of providing mechanical support to the ankle (below
knee cast, Aircast® brace and Bledsoe® boot) in comparison to Tubigrip®, and (2) to compare the
cost of each strategy, including subsequent health care costs.
Methods/design: Six hundred and fifty people with a diagnosis of severe sprain are being identified
through emergency departments. The study has been designed to complement routine practice in
the emergency setting. Outcomes are recovery of mobility (primary outcome) and usual activity,
residual symptoms and need for further medical, rehabilitation or surgical treatment. Parallel
economic and qualitative studies are being conducted to aid interpretation of the results and to
evaluate the cost-effectiveness of the interventions.
Discussion: This paper highlights the design, methods and operational aspects of a clinical trial of
acute injury management in the emergency department.
Background
Sprains of the lateral ligaments of the ankle joint account
for between 3 and 5% of all emergency department (ED)
attendances in the UK [1], with approximately 5600 inju-
ries each day [2]. The injury is painful and incapacitating,
and, for all but the most minor injuries, weight bearing is
difficult to tolerate. Activities of daily living can be signif-
icantly compromised in the first few weeks, and although
acute symptoms resolve, persistent symptoms are
reported to occur in between 30 to 50% of people [3-6].
Persistent symptoms include recurrent sprains, instability,
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developed a classification of severity of ankle injuries [7].
• GRADE I – the ligament is stretched but not torn and the
anterior talofibular ligament is usually involved. The ante-
rior draw test is negative.
• GRADE II – the ligaments are partially torn; laxity may
be present and there is moderate swelling.
• GRADE III – complete rupture of the ligament resulting
in joint instability. The anterior draw test is positive.
The focus of this trial is Grade II and III sprains (referred
to as severe sprains from this point). Severe sprains have
poorer prognosis, and necessitate more intensive manage-
ment than Grade I sprains (minor sprains). Minor sprains
are considered to be self-limiting and require minimal
treatment.
Recent systematic reviews have highlighted the lack of
high quality evidence to support clinicians in managing
severe sprains [2,7]. There are few reliable studies describ-
ing long-term outcome. Most trials required x-ray evi-
dence of talar tilt or an arthrogram for inclusion and are,
therefore, not generalisable to clinical practice in the ED.
Current practice ranges from no intervention, physiother-
apy, and different types of mechanical support to surgical
repair of the ligaments. A recent UK survey of 83 EDs dem-
onstrated the most popular treatments were ice, elevation,
Tubigrip® support stocking and exercise, each of which
was reported as being used in most cases by over 70% of
respondents [8]. In addition, over half of responding
departments reported that crutches, early weight bearing,
and non-steroidal anti-inflammatory drugs were used in
most cases. Follow up was used only in selected cases.
Practice has been gradually changing from immobilisa-
tion of the injured joint to early mobilisation. To aid
mobilisation the use of mechanical supports has been
suggested. These supports vary in the amount of ankle
movement they allow, but all encourage ankle flexion/
extension and aim to minimise inversion/eversion that
theoretically reduces the risk of further ligament injury.
Movement is also proposed as a way of retraining the
ankle proprioception which may reduce recurrent injury
rate [9]. Other hypothesised benefits of mechanical sup-
ports are early restoration of functional mobility, rapid
return to usual activities, reduction of pain because the
joint is stabilised and protected, and improved quality of
life. However, there is also the possibility of discomfort
and inconvenience owing to restriction of joint range, and
delayed healing, skin and circulatory problems.
The present study has two aims
1. To estimate the clinical effectiveness of three different
methods of mechanical support (below knee cast, Aircast®
ankle support and Bledsoe® boot) in comparison to
Tubigrip® in
a. The recovery of mobility (primary outcome)
b. The recovery of usual occupation
c. Avoidance of residual symptoms including recurrent
instability, lasting limitation of physical activity, and need
for further medical, rehabilitation or surgical treatment.
2. To measure the cost of each strategy, including treat-
ment and subsequent health care costs.
The NHS National Co-ordinating Centre for Health Tech-
nology Assessment has guided the selection of treatments.
Tubigrip® has been chosen as the reference treatment
because it is the cheapest and one of the most commonly
used [10]. The Bledsoe® boot is lightweight and incorpo-
rates a novel design to promote ease of walking. However
it is considerably more expensive, and it's clinical and cost
effectiveness is yet to be proven. The below knee cast is
Scotch® Cast is commonly used for casting in the NHS [9].
There is a range of lightweight mechanical supports avail-
able, and we have selected the Aircast® Brace.
Methods
This pragmatic randomised controlled trial is being run in
6 trusts (covering eight hospitals) across the UK. The trusts
are: Birmingham Heartlands and Solihull NHS Trust,
North Bristol NHS Trust, Oxford Radcliffe Hospitals NHS
Trust, South Warwickshire General Hospitals NHS Trust,
University Hospitals Coventry and Warwickshire NHS
Trust and the Worcestershire Acute Hospitals NHS Trust.
Figure 1 provides an overview of the trial method and
patient journey. Multi-centre Research Ethics Committee
approval has been awarded by the Northern and York-
shire Regional Office and local ethical and research gov-
ernance approvals have been obtained. Informed consent
to participate in the trial and allowing researchers to
access hospital records is obtained from all participants.
Study population
The target population is people attending the ED with a
severe sprain of the lateral ligament complex of the ankle.
Inclusion criteria
People who attend with sprain of the ankle who are una-
ble to weight bear, aged 16 years and older, and give
informed consent. Weight bearing is used as a proxy for
severe sprains as clinical grading is not possible in the
acute phase [7]. Flake fractures (<=2 mm) of the lateralPage 2 of 8
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Study design
Normal A&E work-up 
including X-ray to exclude 
fracture if indicated
Grade II & III sprains referred 
to clinic as per normal
practice. Provided with 
information and invitation to 
join trial
Tracking system instituted
to determine bias due to 
clinic non-attendance 
Follow up clinic 2-3 days 
later: Consent
No, reasons for decline 
recorded.
Treatment as normal
Yes
Baseline assessment and randomisation
Aircast® Brace Bledsoe® Boot Tubigrip® Below Knee 
Cast
Follow-up assessments at 4 weeks, 12 weeks and 9 months
Not eligible
Grade I sprains 
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tissue injuries [11].
Exclusion criteria
Age less than 16 years old, ankle or other fracture sus-
tained in addition to the sprain (such as to the wrist, head
etc). An x-ray is used to exclude fracture where this is clin-
ically indicated and as guided by the Ottawa guidelines
[12]. People who can weight bear and those with fractures
are ineligible for the trial, and are managed in accordance
with normal local practices. Age is used as an exclusion
criterion because of the complications involved in the
management of epiphyseal injuries (growth plate inju-
ries). Growth plate injuries would not normally be man-
aged using the treatments being tested [13].
Patients are also excluded if they have a contra-indication
to any of the four arms of the trial. This is most likely to
occur if a patient has a DVT, high risk of DVT or other cir-
culatory disturbance. Other contra-indications include
poor skin viability preventing splinting or casting. The
decision to exclude on these criteria is made by the attend-
ing clinician.
The process of identifying participants
A standard approach to identifying potential participants
has been instituted across all participating centres. The
approach was designed in consultation with the depart-
ments to dovetail with current procedures, and eradicate
duplication of clinical and research data collection. The
attending clinician (nurse practitioner, physiotherapist or
doctor) assesses weight-bearing status. These data are
recorded on a form that includes details of the remainder
of the clinical examination, including if indicated, x-ray
results. At this stage, people able to weight bear are
excluded.
The attending clinician gives a brief explanation of the
trial, an information pack, and arranges an appointment
at a follow-up clinic two to three days later. Delay is an
accepted practice in the application of mechanical sup-
ports, allowing for the resolution of acute swelling. It also
filters out patients in whom the diagnosis of severe sprain
at initial contact was incorrect, and gives participants suf-
ficient time to consider whether they wish to participate in
the trial. A physiotherapist who staffs the follow-up clinic
is responsible for checking eligibility and providing a fur-
ther opportunity for patients to ask questions. If appropri-
ate, the physiotherapist recruits the patients, contacts the
randomisation centre, and arranges application of the
treatments. Reasons for declining to participate in the trial
are recorded.
Assessing the generalisability of the results
Data on all ankle sprains attending the participating EDs
during the recruitment period are collected using a stand-
ardised proforma. A copy of this proforma, which is
entered into the medical record, is anonymised and
passed to the research team. It provides descriptive data
on the injury pattern, occupation, age, and sex of patients,
including those who are ineligible or decline trial partici-
pation at various time points. Completed proformas are
audited against ED attendance records to check whether
attending clinicians have referred appropriate patients to
the follow-up trial clinics. This allows clinicians who are
unfamiliar with the trial to be identified and approached
individually to be briefed on trial procedures.
Treatment allocation
Randomisation is stratified by centre and provided via a
phone-in service, which utilises a computer generated ran-
dom allocation. Allocation concealment, which shields
people who enter patients into a trial from knowing future
allocations, is thereby ensured. The randomisation service
is independently administered and quality controlled by
the Birmingham Cancer Trials Unit.
Treatment protocol
The mechanical supports are fitted to each individual by a
trained health professional (physiotherapist, nurse or
plaster technician) in the follow-up clinic, to ensure com-
fort and correct fit. Participants are provided with stand-
ardised written and verbal instructions including when to
remove the support, encouragement of normal walking
with limits of tolerance, simple exercise advice, what to do
in the event of experiencing difficulties with the support,
and washing instructions. The protocols for duration of
support, weight-bearing status, and activity have been
determined by the manufacturers recommendations and
the results of a national survey of practice completed in
the planning phase of the trial [8]. Treatments are applied
within three days of the injury, and within an hour of
randomisation.
Other treatments
All other treatments are standardised and include the pro-
vision of crutches, advice to elevate and pain relieving
medications if needed. Withdrawal of the latter
treatments would be inappropriate as they constitute nor-
mal and accepted care. Physiotherapy is not provided as
part of the trial treatment protocol, and is not part of rou-
tine care provided in the participating centres [9]. If the
participant receives these types of treatment in addition to
the trial protocol, this is recorded as an outcome.
Baseline and outcome measures
Clinical status is measured at baseline, 4 weeks, 12 weeks
and 9 months. The baseline assessment also includes datePage 4 of 8
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pre-injury abilities including usual levels of mobility,
engagement in sporting activity, usual occupation and
employment (including hours worked and type of work
undertaken) and completion of the baseline version of
the outcome questionnaires.
The selection of outcome measures is based on a system-
atic review completed during the preparatory stage [14],
and are shown in Table 1. There is a paucity of informa-
tion on the psychometric properties of self-completed
questionnaires for ankle conditions. The Foot and Ankle
Outcome Score (FAOS) is a questionnaire that ascertains
functional limitations (including mobility) and the sever-
ity of other symptoms after ligament sprains, and has evi-
dence of validity and reliability [10]. Previous versions
have been validated against objective tests of ankle func-
tion [15]. The Functional Limitations Profile (FLP) is the
British version [16] of the Sickness Impact Profile [17]. We
are using the FLP occupation and mobility sub-scales to
provide more detailed information on the impact of the
injuries and treatments including adaptations that occur
after the injury. The FLP has not been used in studies of
ankle injuries previously. Health related quality of life will
be measured using the SF-12 version 1 and EQ-5D [18].
Return to normal occupation and leisure activities will be
recorded as the date that people return to work and nor-
mal activities. Patients are asked to make a record of sig-
nificant dates on a calendar to aid recall. The effectiveness
of these calendars is being tested in a separate study.
Timing of follow-up
The mechanical supports are likely to have maximal
impact and benefit during the first three months of recov-
ery, and this time period is defined as the primary time
point. We anticipate that some participants will still be
wearing the mechanical support at 4 weeks. The natural
time course of recovery of ankle sprains is for functional
limitations to stabilise between 3 and 9 months and it is
expected that the difference between treatments will nar-
row in the longer term as the majority of people will
recover [3,5,6]. Participants will be followed to 9 months
to ensure that there are no longer-term complications
from injury or their treatments.
Follow-up and masking
Follow-up data are collected by postal questionnaire. We
have implemented an intensive approach to follow-up.
Participants are mailed a follow-up questionnaire, and if
a response is not received within one week, they are tele-
phoned to ensure they have received the questionnaire. A
second questionnaire is mailed if necessary. If there is still
no response, the participant is contacted one week later,
and a core set of outcomes are collected over the tele-
phone. All follow-up data are collected and analysed by
individuals who are independent of the recruitment, ran-
domisation, baseline assessment and are masked from the
treatment provision. This level of masking will be main-
tained until final analysis of the data has been completed.
The only exception to this rule will be if the data monitor-
ing committee require unmasked data, and in this circum-
stance, only the independent Chairperson will be aware of
assignments.
Quality assurance
Trial procedures are audited at regular intervals to ensure
compliance with the protocol. Maintaining trial profile
and competence in trial procedures is challenging in the
ED, because of a high turn-over of staff and a diversity in
the staff groups dealing with injuries in different hospi-
tals. To combat these difficulties, training is provided on
cycles that coincide with staff rotation, as well as various
other time points (e.g. in-service training).
Data analyses
The analysis will be conducted as intention to treat. An
analysis of all people who completed the trial will be
undertaken, and in addition, a sensitivity analysis will be
undertaken to assess the range of potential biases that
could result from loss to follow up or withdrawal. Numer-
ical and graphical summaries of all the data will be
Table 1: Outcome measures
Outcome Outcome measure
Functional limitations and severity of symptoms after ligament sprains Foot and Ankle Outcome Score (FAOS)
Impact of injuries and treatments including adaptations that occur after 
injury
Functional Limitations Profile (FLP) occupation and mobility sub scales
Health related quality of life Short Form 12 version 1 (SF-12 v1)
Health related quality of life EuroQol (EQ-5D)
Health economics Resource Use Questionnaire
Return to normal occupation and leisure activities Date of return to work and normal activities recorded on a trial 
calendarPage 5 of 8
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at the clinic visit, questionnaire and individual level.
Logistic and log-linear multinomial regression models
will be used to provide estimates of the recovery rates and
the prevalence of residual symptoms, with confidence
intervals. As there are multiple centres and repeat assess-
ment, random effect (or hierarchical) models will be used
to investigate the components of variation. The common
current and cheapest therapy is Tubigrip®, so each of the
three other treatments will first be compared with it. Any
treatments found to be more effective than Tubigrip® will
be compared with each other. Regression modelling will
allow an assessment of factors that might indicate the
appropriate choice of treatment. As these analyses are pre-
specified, issues of multiple comparisons are minimal.
The sensitivity of the above analyses to missing data at
various levels will be assessed and quantified using mod-
ern statistical methods for incomplete multivariate data
[19].
Economic analysis
Severe sprains may have a range of direct cost conse-
quences across primary and secondary health care, they
may also have cost consequences for patients themselves
in terms of their personal expenditure and return to work.
The costing study will seek to adopt a broader societal per-
spective, including patient costs, when estimating differ-
ences in the cost of resources used in the four arms of the
trial. The economic analysis will compare resource use
(costs) with any measurable changes in health outcomes
(benefits). The health outcomes of the four technologies
will be measured in terms of changes in specific disease
parameters and validated measures of health-related qual-
ity of life (HRQL). Any uncertainties in the cost and out-
comes data will be incorporated into a sensitivity analysis.
The cost of each mechanical support protocol will be
determined through observation and will include staff
time, overheads, equipment and transport; plus follow-up
visits to hospital, GP surgeries, physiotherapists or others.
The consequences for patients in terms of GP and hospital
visits, including travel expenses and time off work, and
expenditure on aids or private practitioner input are
obtained from structured resource use questions added to
patient follow-up questionnaires. Further treatments
recorded include pain relieving medications, anti-inflam-
matory and other topical agents, bandages, supports or
footwear. Patients are also asked to distinguish whether
these are NHS-funded or private treatment paid for by the
individual or private provider. Patient self-reported infor-
mation on service use has been shown to be accurate in
terms of intensity of use of different services [20]. Hospital
notes and records will also be audited for information on
service use. The cost of primary and hospital services will
be estimated from a variety of sources, including the
finance departments of the trial hospitals and services
concerned and national sources [21,22]. Differences in
resource use and outcomes are ascertained in follow-up
questionnaires at 12 weeks and 9 months.
The appropriate technique of economic evaluation will
depend on the results of the study [23]. The simplest even-
tuality would be where the least expensive intervention is
found to be better on at least one outcome measure and
no worse on any other i.e. dominant. Another is where
two interventions have the same outcomes in which case
cost-minimisation analysis will be used to compare the
two. However, where an intervention is clearly better in
terms of outcome but is also more costly, a different
approach is required. One accepted method is to compare
the different interventions in terms a single outcome
measure identified as clinically important for the condi-
tion being treated. The primary outcome meets this
requirement. Therefore, the costs per unit improvement in
mobility will be used to provide an estimate of overall
cost-effectiveness; average and incremental (relative to ref-
erence treatment) cost-effectiveness ratios will be estimate
for the different treatments used. However, this approach
does not allow comparison with other types of interven-
tion/condition combinations and also does not consider
the value (utility) of differences in improvement in health
status. In the present study, the EQ-5D will be used to gen-
erate such utility scores that can be compared to costs. A
cost-utility analysis will estimate outcomes in terms of dif-
ferences in quality-adjusted life years (QALYs), represent-
ing the period of life subsequent to a health care
intervention weighted or adjusted for the quality of life
experienced by the patient during that period, and com-
pare these with cost for the four interventions [23]. The
cost-utility analysis will present the incremental cost of
the extra benefit gained both in summary form in terms of
incremental cost per QALY, and also using a 'disaggre-
gated' approach where the extra costs are presented along-
side the HRQOL dimensions such as pain.
Sample size
Although there was a paucity of published data available
to inform the sample size estimate at the outset of the
trial, the preliminary phase of the study has enabled us to
make a more accurate estimation of the sample size
required. The presented estimate is based on a standard
sample size calculation for a two-sample t-test with equal
variances and a significance level of 0.05, using the vari-
ance estimated from an ANOVA of the 4-week data (n =
100). The minimal clinically important difference is set at
10 percent, which represents a small to moderate effect
size. A target of 600–650 participants will allow us to
detect clinically important outcomes at 4 and 12 weeks.Page 6 of 8
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in the primary outcomes, and have sufficient power to
detect differences in a range of secondary outcomes at
80% power. To account for the possibility of loss to fol-
low-up, the estimate includes an inflation of 20%. How-
ever, the trial should be able to report whether any of the
treatments have a sustained negative effect on outcome at
9 months. We are taking a pragmatic approach to estimat-
ing the sample size, and the Data Monitoring Committee
are reviewing assumptions underlying the calculation at
6-monthly intervals.
Qualitative sub-study
A purposive sample of randomised patients will be inter-
viewed to obtain qualitative data on the patients' experi-
ences of the various treatments in a semi-structured
interview. Patients will also be asked for their views on
their willingness to pay a deposit for the boots/splints to
encourage their return. Up to 20 patients will be inter-
viewed using a semi-structured format. The data will be
analysed using thematic content analysis.
Conclusions
We have described the protocol and conduct of a large
scale UK randomised controlled trial of mechanical sup-
ports for the management of acute severe ankle sprains.
There has been a paucity of good quality research con-
ducted to date, which may be partly explained by the chal-
lenges implicit to studying acute events within EDs
[24,25]. These include a very short window of opportu-
nity in which patients satisfy the criteria of acute injury
and reliance on attending clinical staff to identify and
approach for inclusion potential participants who are
often in a state of discomfort. The trial is currently in the
middle of the recruitment phase and is running well. Trial
procedures have been well received by both patients and
clinicians. Much effort has gone into maintaining the pro-
file of the trial and disseminating trial procedures across
all disciplines of ED staff (e.g. doctors, nurses, reception
staff and plaster technicians). This has been paramount to
the success of the trial. By referring potential patients to
the follow-up trial clinics ED personnel, with no direct
involvement in the trial, play a vital role in the trial proc-
ess. The intense follow-up has produced good completion
rates. Using a pragmatic approach to sample size estima-
tion was useful, in particular, re-estimation after an ade-
quate run in period, and is recommended where little
prior data exists.
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